Reevaluating Migraine Treatment: Beyond Frequency Reduction
- MigraineMind
- Nov 30, 2025
- 1 min read
Research Summary
A recent study published in the journal Headache challenges the current reimbursement criteria for anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies used in migraine treatment. Typically, treatment continuation depends on a significant reduction in monthly migraine days, but this study suggests many patients experience other valuable benefits. Conducted at two Spanish hospitals, the study identified 106 "false nonresponders" who did not meet strict criteria but showed significant improvement in multiple areas, such as a 60% improvement in disability scores and 46% resolution of medication-overuse headaches. The findings highlight the importance of considering broader treatment benefits to avoid premature discontinuation of effective therapies.
Study Details
👥 Research Team: Muñoz-Vendrell A et al.
📚 Published In: Headache
📅 Publication Date: 2025 Nov 28
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.